4//SEC Filing
Adamas Pharmaceuticals Inc 4
Accession 0001209191-17-022342
CIK 0001328143operating
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 5:06 PM ET
Size
7.5 KB
Accession
0001209191-17-022342
Insider Transaction Report
Form 4
Went Gregory T
DirectorChief Executive Officer10% Owner
Transactions
- Sale
Common Stock
2017-03-21$17.03/sh−2,807$47,803→ 166,526 total
Holdings
- 195,392(indirect: By Trust)
Common Stock
- 80,000(indirect: By Trust)
Common Stock
- 80,000(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
- [F2]The shares were sold at prices ranging from $16.96 to 17.215. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Adamas Pharmaceuticals Inc
CIK 0001328143
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001328143
Filing Metadata
- Form type
- 4
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 5:06 PM ET
- Size
- 7.5 KB